About Me

Biomedical scientist, PhD candidate, and self-taught investor at the intersection of life sciences and capital markets.

My Story

Building Bridges Between Discovery and Impact

I am a Brazilian biomedical scientist completing my PhD at CEITEC (Central European Institute of Technology) in Brno, Czech Republic. Over the past 13 years in research, I have contributed to studies published in Blood, Journal of Clinical Oncology, and Leukemia. These experiences have shaped my interest in connecting deep mechanistic biology with clinically meaningful questions.

I enjoy moving from hypothesis generation and experimental design to data interpretation, critical evaluation of evidence, and the identification of biologically relevant signals. My long-term goal is to help translate robust biological insights into better ways to detect, understand, monitor, and treat diseases.

Beyond the laboratory, I founded Scienarq to communicate complex biomedical science to researchers, students, clinicians, investors, and science-curious audiences through YouTube and Instagram.

I also manage a verifiable investment portfolio that has achieved a +12.75% annualized CAGR (+79% over the last 5 years). The portfolio is publicly available for review, and investors may choose to follow or replicate my positions.

These pursuits reflect my mindset: curiosity, analytical rigor, probabilistic thinking, and long-term impact.

Pedro Faria Zeni in the lab

Core Values & Strengths

Core values guide my decisions — core strengths define how I create impact.

Core Values

I value work that advances how we detect, understand, monitor, and treat disease.

I value rigorous evaluation of data over hype, authority, or fashionable narratives.

I am energized by connecting ideas across disciplines and generating new hypotheses.

I value broad exposure to mechanisms, technologies, and clinical problems over narrow specialization.

I value working in environments where the purpose feels authentic and meaningful.

I want to remain intellectually grounded in biomedical science, even if my role becomes more strategic than technical.

I value creating impact by designing, guiding, and enabling science through teams and collaborations.

I value building things that deepen and compound over time rather than chasing immediate visibility.

Core Strengths

Creating original scientific ideas and identifying non-obvious connections.

Combining molecular biology, clinical relevance, biomarkers, and strategic considerations.

Questioning assumptions, identifying weaknesses in evidence, and thinking probabilistically.

Distinguishing important questions from merely interesting ones.

Explaining complex biomedical concepts clearly to different audiences.

Thinking beyond mechanism toward clinical utility and patient outcomes.

Forming your own conclusions rather than relying on consensus.

Moving comfortably between research, communication, and investment thinking.

Career Path

My Journey

Independent portfolio manager on eToro — available for copy trading. My portfolio has a verified track record: +79% total return over 5 years (+12.75% CAGR). I'm a value investor, combining fundamental thesis-driven analysis with diversification and risk assignments — all executed and copyable directly on the eToro platform.
Scienarq — multi-platform science communication (YouTube, Instagram, TikTok). Translating complex biomedical research for broad audiences.
CEITEC, Masaryk University, Brno, Czech Republic (with affiliation to University Hospital Brno, FN Brno). My work focused on the role of long non-coding RNAs (lncRNAs) in B-cell malignancies, B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), and collaborative studies on microRNAs in lymphomas. Research findings were published in Blood, Journal of Clinical Oncology (JCO), and Leukemia.
UNICAMP (State University of Campinas), Brazil — Master's in Functional & Molecular Biology, conducted at Boldrini Children's Hospital (Campinas, SP). My research focused on immunoengineering strategies for pediatric hematological malignancies and the molecular mechanisms of lymphocyte activation.
My continuing education spans over a decade of focused training across the world's leading institutions, covering the full spectrum from foundational molecular biology to specialized immunoengineering and precision medicine.

Core Molecular Biology — MIT (2023–2024): A three-part series — DNA Replication and Repair, Transcription and Transposition (including CRISPR), and RNA Processing and Translation — providing systematic training in the central dogma at the graduate level.

Advanced Wet-Lab Techniques — EMBL, Germany (2023): Hands-on EMBO Practical Course on RNA FISH, from classical to single-molecule approaches, covering dye conjugation, probe labeling, smFISH, and image analysis.

Precision Medicine & Cancer Biology — UCSF, OSU, Harvard, Columbia (2014–2017): Training in genomic medicine, tumor biology, cancer science, principles of biochemistry, virology, and viral pathogenesis — building a foundation for translational oncology research.

Immunology — Rice University (2014): A two-part series covering pathogen recognition, MHC and antigen presentation, T cell development, cytokines, and cellular-organ interaction.

Biotechnology & Molecular Techniques — USP, FIOCRUZ, Portal Educação, IPED (2013–2016): Practical and theoretical training in molecular biology, biochemistry, cell culture (including 3D culture), PCR and Sanger sequencing, biosafety (GMOs, biological risks), pharmacogenetics, biotechnological methods, and laboratory test interpretation.

Special Topics — Columbia, Emory, UNIMELB (2013): Virology, HIV/AIDS, dengue, and epigenetic control of gene expression.

This collection of courses reflects deliberate, self-directed investment in building expertise across molecular biology, immunology, cancer biology, and biotechnology.
Specialization in Genomic Data Science (Johns Hopkins University, Coursera): I learned about programming, NGS, GWAS, genomic variation, and computational analysis of high-throughput genomic data.
Universidade Tiradentes (UNIT), Brazil. I acquired a strong foundation in both basic and clinical sciences, along with hands-on experience in clinical laboratory diagnostics. This training enables me to bridge basic research, clinical application, and biotechnology development.
Recognition

Awards & Service

iGEM 2025 Jury Member

Selected to evaluate synthetic biology projects at the international iGEM competition (the largest synthetic biology convention in the world), assessing scientific merit and translational potential.

Biotech Consultant

De-risked ChemiCare's lead program by demonstrating insufficient evidence for ORAI1 targeting, preventing substantial downstream preclinical investment.

Top-Tier Publications

First-author and co-author publications in Blood, Journal of Clinical Oncology, and Leukemia — the most selective journals in hematology and oncology.